AbbVie Acquires Nimble Therapeutics for $200M to Expand Autoimmune Treatment Pipeline
AbbVie has announced its acquisition of Nimble Therapeutics, a Roche spinout, for $200 million, with additional undisclosed interim and milestone payments[1][2]. This acquisition enables AbbVie to expand its autoimmune treatment portfolio by gaining access to Nimble's innovative oral peptide synthesis platform and its promising early-stage pipeline[1]. Nimble, based in Madison, Wisconsin, focuses on developing treatments for immune diseases such as psoriasis and inflammatory bowel disease, with its lead candidate, an IL23R inhibitor, currently in preclinical development[2]. This acquisition follows a series of strategic buyouts by AbbVie, including the purchase of Aliada Therapeutics and Celsius Therapeutics, underscoring its active pursuit of advancing immune system therapies[1].
References
Explore Further
What specific advantages does Nimble Therapeutics' peptide synthesis platform bring to AbbVie's existing autoimmune treatment pipeline?
How might the integration of Nimble Therapeutics alter AbbVie's competitive position in the autoimmune disease treatment market?
What are the anticipated milestones that could trigger additional payments in AbbVie's acquisition of Nimble Therapeutics?
In what ways could Nimble's oral IL23R inhibitor potentially improve upon existing injectable treatments for autoimmune diseases?
Which specific autoimmune conditions other than psoriasis and inflammatory bowel disease could benefit from Nimble Therapeutics' peptide-based therapies?